Written questions by Morrison.

How many take-home naloxone kits were distributed by local authorities in England in 2022/2023.

Access to naloxone is vital to respond to the threat of synthetic opioids and to prevent drug related deaths. The Government has long supported expanded provision of naloxone, with guidance and funding, and this has contributed to a significant growth in the amount of naloxone available in the community to reverse opioid overdoses.In England, take-home naloxone supply is recorded by the National Drug Treatment Monitoring System, which drug and alcohol treatment services complete. It only records supply of take-home naloxone to people in registered treatment and does not record other people who may also be supplied with naloxone, like friends or family of people in treatment. Local authorities may also distribute naloxone via other routes besides substance misuse services.We have recently published statistics on the distribution of naloxone to those in registered treatment from 2024 to 2025. The statistics can be found in the data tables in Table 1.7: naloxone distribution and use to reverse overdose, namely in Table 1.7a: naloxone issued, at the following link:https://www.gov.uk/government/statistics/substance-misuse-treatment-for-adults-statistics-2024-to-2025This is the first time that figures on the distribution of naloxone have been published and, therefore, trends in its distribution over time cannot yet be assessed. We intend to continue publishing statistics on naloxone distribution each year.The Department launched a public consultation in December 2025 on further legislative options to expand access to take-home and emergency use naloxone. As part of this consultation, we are proposing specific data reporting requirements to enable more consistent reporting across the United Kingdom on the supply of take-home naloxone. The consultation closes on the 9 March 2026.

How many take-home naloxone kits were distributed by local authorities in England in 2023/2024.

Access to naloxone is vital to respond to the threat of synthetic opioids and to prevent drug related deaths. The Government has long supported expanded provision of naloxone, with guidance and funding, and this has contributed to a significant growth in the amount of naloxone available in the community to reverse opioid overdoses.In England, take-home naloxone supply is recorded by the National Drug Treatment Monitoring System, which drug and alcohol treatment services complete. It only records supply of take-home naloxone to people in registered treatment and does not record other people who may also be supplied with naloxone, like friends or family of people in treatment. Local authorities may also distribute naloxone via other routes besides substance misuse services.We have recently published statistics on the distribution of naloxone to those in registered treatment from 2024 to 2025. The statistics can be found in the data tables in Table 1.7: naloxone distribution and use to reverse overdose, namely in Table 1.7a: naloxone issued, at the following link:https://www.gov.uk/government/statistics/substance-misuse-treatment-for-adults-statistics-2024-to-2025This is the first time that figures on the distribution of naloxone have been published and, therefore, trends in its distribution over time cannot yet be assessed. We intend to continue publishing statistics on naloxone distribution each year.The Department launched a public consultation in December 2025 on further legislative options to expand access to take-home and emergency use naloxone. As part of this consultation, we are proposing specific data reporting requirements to enable more consistent reporting across the United Kingdom on the supply of take-home naloxone. The consultation closes on the 9 March 2026.

How many take-home naloxone kits were distributed by local authorities in England in 2024/2025.

Access to naloxone is vital to respond to the threat of synthetic opioids and to prevent drug related deaths. The Government has long supported expanded provision of naloxone, with guidance and funding, and this has contributed to a significant growth in the amount of naloxone available in the community to reverse opioid overdoses.In England, take-home naloxone supply is recorded by the National Drug Treatment Monitoring System, which drug and alcohol treatment services complete. It only records supply of take-home naloxone to people in registered treatment and does not record other people who may also be supplied with naloxone, like friends or family of people in treatment. Local authorities may also distribute naloxone via other routes besides substance misuse services.We have recently published statistics on the distribution of naloxone to those in registered treatment from 2024 to 2025. The statistics can be found in the data tables in Table 1.7: naloxone distribution and use to reverse overdose, namely in Table 1.7a: naloxone issued, at the following link:https://www.gov.uk/government/statistics/substance-misuse-treatment-for-adults-statistics-2024-to-2025This is the first time that figures on the distribution of naloxone have been published and, therefore, trends in its distribution over time cannot yet be assessed. We intend to continue publishing statistics on naloxone distribution each year.The Department launched a public consultation in December 2025 on further legislative options to expand access to take-home and emergency use naloxone. As part of this consultation, we are proposing specific data reporting requirements to enable more consistent reporting across the United Kingdom on the supply of take-home naloxone. The consultation closes on the 9 March 2026.

Whether his Department has an expected timeline for publishing the Modern Service Framework for Cardiovascular Disease.

We expect to publish the new Cardiovascular Disease Modern Service Framework (CVD MSF) later this year.The Department and NHS England are engaging widely with stakeholders to co-produce the CVD MSF, ensuring that experts, people, and communities are at the heart of its development.

What assessment they have made of variations in access to Tirzepatide (Mounjaro) across Integrated Care Boards; and what steps they are taking to ensure consistency in prescribing for eligible patients.

Tirzepatide, brand name Mounjaro, is recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of both type 2 diabetes and obesity.Integrated care boards (ICBs) are legally required to fund NICE-recommended medicines, including obesity treatments, within three months of final approval. NICE granted a phased rollout of tirzepatide for obesity to manage National Health Service resources and establish new care pathways. ICBs have been legally required to fund tirzepatide for obesity so that prescribers can offer the treatment to eligible patients in specialist weight management services since March 2025 and in primary care from 23 June 2025. NHS England is providing support for ICBs, including providing:- additional funding to support the delivery of services within primary care and the cost of obesity medicines in line with interim commissioning guidance; and- a centrally funded wraparound care service ‘Healthier You: Behavioural Support for Obesity Prescribing’ for primary care to refer patients to. We do not hold information on whether each ICB provides access to specific medicines in its locality. ICBs are responsible for ensuring they meet their legal duties, including making funding for NICE-recommended medicines available.

Whether he has considered the potential merits of conducting a review into the law of causation in clinical negligence, with a focus on increasing support and protection for families with late family members who were misdiagnosed or not diagnosed at all.

As announced in the 10 Year Health Plan for England, David Lock KC is providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims. David Lock KC has not been specifically asked to conduct a review into the law of causation in clinical negligence as part of his work, but he is able to consider all aspects of the way clinical negligence law operates as part of his review.

What steps his Department is taking to ensure equitable regional access to NICE-recommended digital cognitive behavioural therapy for insomnia, including Sleepio.

It is for local integrated care boards to decide whether treatments such as cognitive behavioural therapy or digital solutions such as Sleepio should be offered to their local populations as a treatment for insomnia.NHS Talking Therapies for anxiety and depression offer low-intensity therapy which may include interventions around sleep hygiene. Individuals who are experiencing symptoms of anxiety and/or depression can be referred by their general practitioner, or can self-refer, to NHS Talking Therapies. People can also access helpful resources on sleep problems on the Every Mind Matters website at the following link:https://www.nhs.uk/every-mind-matters/mental-health-issues/sleep/

What processes are in place for families to seek remedial action against GPs who fail to correctly diagnose patients who shortly afterwards pass away.

If a family wishes to make a formal complaint about services provided by a general practice, they should write to the practice manager. If the family is not comfortable raising a complaint directly, they can instead raise their concerns with their local National Health Service integrated care board, with NHS England or with their local Healthwatch, the independent consumer champion for health and social care. Further information about the NHS complaints procedure and Healthwatch can be found, respectively, at the following two links:www.nhs.uk/using-the-nhs/about-the-nhs/how-to-complain-to-the-nhswww.healthwatch.co.uk

Whether his Department has made an assessment of the potential impact of target-driven GP contracts on the quality of care and doctor-patient relationships.

The GP Contract sees practices receive funding through a range of income streams.The Quality and Outcomes Framework (QOF) is an optional pay-for-performance scheme that makes up approximately 10% of overall practice income. The indicators and thresholds included in the QOF are developed in accordance with National Institute for Health and Care Excellence guidelines, underpinned by a robust evidence base. Thresholds are designed to be attainable, while encouraging and incentivising practices to provide the best possible care. Thresholds are aspirational rather than a contractual obligation.As part of our recently published Medium-Term Planning Framework, we have introduced a new and ambitious target to ensure all urgent appointments are provided on the same day, so that patients requiring urgent care are prioritised. The Department continues to engage with general practitioners broadly to ensure the targets are achievable, reflect the needs of the populations they serve, and to understand barriers to meeting this target.

What procedures are in place to ensure that savings thresholds in relation to care costs are communicated to the public at both local and national level.

The Department undertakes an annual review of the capital limits and the social care allowances within the adult social care charging system.The capital limits determine eligibility for means-tested local authority support with care costs, and the social care allowance rates set the statutory minimum income that individuals must retain after charging.To communicate the rates for the upcoming financial year, 2026/27, the Department will publish a Local Authority Circular on the GOV.UK website, in early 2026. Local authorities should reflect these updates in their publicly available charging policies, ensuring consistent communication at both a local and national level.

What steps are being taken to help ensure that international medical students and trainees working in UK health services are protected from racial discrimination and workplace hostility.

Any form of racism or discrimination is unacceptable and has no place in our National Health Service.The NHS Equality, Diversity and Inclusion Improvement Plan, published in 2023, recognises that we benefit from the skills, expertise, and commitment of internationally recruited healthcare professionals and highlights the important role that NHS organisations have to play in making staff feel welcomed and valued at the start of their career. NHS organisations are expected to review their data by protected characteristics on bullying, harassment, discrimination, and violence and make plans to improve staff experience year on year.Additionally, as set out in the 10-Year Health Plan, we will introduce a new set of staff standards for modern employment which will include tackling racism and reducing violence against staff. The standards will be underpinned by the NHS Oversight Framework and the Care Quality Commission assessment framework.

Whether he will have discussions with Cabinet colleagues on the potential merits of extending the Civility Saves Lives initiative to other public-facing services, including Jobcentre Plus and local authority housing departments.

The Civility Saves Lives initiative highlights the importance of behaviours in the workplace and the impact that rudeness can have on performance, wellbeing, and patient safety. It is a movement created by healthcare professionals, rather than a national initiative developed and rolled out by the Department or NHS England.There are currently no plans to discuss the initiative with colleagues in other Government departments.

What steps are being taken to reduce reliance on digital consultations and ensure equitable access to in-person appointments, particularly for those with mental health conditions or language barriers.

National Health Service organisations must ensure that all patients have equitable access to care, and that decisions or policies do not unfairly disadvantage people or lead to an increase in inequalities. All NHS organisations are legally obliged to not discriminate against patients or staff. This means that a non-digital solution should be available for those patients who cannot or do not wish to engage digitally, including those with mental health conditions or language barriers. These non-digital routes must be available for all services provided by NHS organisations.

What steps his Department is taking to embed trauma-informed practice across the NHS, including in GP surgeries and refugee health clinics.

Recognising that asylum seekers may require additional mental health support, including for trauma-related mental health issues, the Department works together with NHS England and the Home Office to provide additional guidance and support where required.Examples of national and local interventions aimed at maintaining and improving the emotional wellbeing and mental health of individuals seeking asylum are available at the following link:https://www.gov.uk/government/publications/asylum-mental-health-workstreams-tools-and-case-studies/workstreams-tools-and-case-studies-by-the-home-office-asylum-mental-health-and-wellbeing-team-accessible

Whether his Department has plans to increase funding for (a) respite care and (b) community-based support for unpaid carers.

The Government recognises the vital role of unpaid carers and is committed to ensuring they have the support they need.The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, which can include respite support for carers.To help local authorities fulfil their duties, including to unpaid carers, the 2025 Spending Review allows for an increase of over £4 billion of funding available for adult social care in 2028/29 compared to 2025/26.

Whether his Department plans to provide funding for specialist dementia leads within GP surgeries.

The National Institute for Health and Care Excellence’s (NICE) guideline NG97 recommends that individuals should be referred to a specialist dementia diagnostic service, such as a memory clinic or community old age psychiatry service, if reversible causes of cognitive decline have been investigated and dementia is still suspected.The Dementia Care Pathway: Full implementation guidance emphasises the need to ensure general practitioners (GPs) are supported in providing dementia diagnosis with education and training programmes, such as Dementia Revealed: What Primary Care Needs to Know, a resource for GPs and practice nurses who have no previous experience of diagnosing and treating dementia.Our health system has struggled to support those with complex needs, including those with dementia. Under the 10-Year Health Plan, those living with dementia will benefit from improved care planning and better services.We will deliver the first ever Frailty and Dementia Modern Service Framework to deliver rapid and significant improvements in the quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia and will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.

What steps he is taking to ensure a strategic approach to biomedical research into myalgic encephalomyelitis and chronic fatigue syndrome.

The Department funds research through the National Institute for Health and Care Research (NIHR).We are committed to working with the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), community to identify and address barriers to research, with the ambition of supporting more research and capacity-building programmes. As part of our approach, together with the Medical Research Council (MRC), we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS Final Delivery Plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including ME/CFS and long COVID, in November to stimulate further research in this field.We have previously discussed ringfenced funding with the ME/CFS community during the development of the Final Delivery Plan for ME/CFS, as well as at subsequent meetings and roundtables on ME/CFS and long COVID. However, this is not usual practice for research funders as applications in all areas should compete for the funding available to uphold transparency and accountability. The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Our position is that welcoming applications on ME/CFS to all programmes enables maximum flexibility both in terms of the amount of research funding and the type of research which can be funded.There has been no specific comparative review on the level of funding for research into ME/CFS compared to other illnesses. The Department invests over £1.6 billion each year on research through the NIHR, including on ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

If he will consider ringfencing funding for research into myalgic encephalomyelitis.

The Department funds research through the National Institute for Health and Care Research (NIHR).We are committed to working with the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), community to identify and address barriers to research, with the ambition of supporting more research and capacity-building programmes. As part of our approach, together with the Medical Research Council (MRC), we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS Final Delivery Plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including ME/CFS and long COVID, in November to stimulate further research in this field.We have previously discussed ringfenced funding with the ME/CFS community during the development of the Final Delivery Plan for ME/CFS, as well as at subsequent meetings and roundtables on ME/CFS and long COVID. However, this is not usual practice for research funders as applications in all areas should compete for the funding available to uphold transparency and accountability. The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Our position is that welcoming applications on ME/CFS to all programmes enables maximum flexibility both in terms of the amount of research funding and the type of research which can be funded.There has been no specific comparative review on the level of funding for research into ME/CFS compared to other illnesses. The Department invests over £1.6 billion each year on research through the NIHR, including on ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

If he will make a comparative review into the adequacy of the level of funding for research into myalgic encephalomyelitis compared to other illnesses.

The Department funds research through the National Institute for Health and Care Research (NIHR).We are committed to working with the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), community to identify and address barriers to research, with the ambition of supporting more research and capacity-building programmes. As part of our approach, together with the Medical Research Council (MRC), we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS Final Delivery Plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including ME/CFS and long COVID, in November to stimulate further research in this field.We have previously discussed ringfenced funding with the ME/CFS community during the development of the Final Delivery Plan for ME/CFS, as well as at subsequent meetings and roundtables on ME/CFS and long COVID. However, this is not usual practice for research funders as applications in all areas should compete for the funding available to uphold transparency and accountability. The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Our position is that welcoming applications on ME/CFS to all programmes enables maximum flexibility both in terms of the amount of research funding and the type of research which can be funded.There has been no specific comparative review on the level of funding for research into ME/CFS compared to other illnesses. The Department invests over £1.6 billion each year on research through the NIHR, including on ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

What assessment his Department has made of the adequacy of dementia-specific training provided to primary care staff.

We want all health and care staff to have received the appropriate training to provide high quality care to people with dementia. Employers in the health system are responsible for ensuring that their staff are trained to the required standards to deliver appropriate treatment for patients.The required training needs are set out in the Dementia Training Standards Framework, which is available at the following link:https://www.skillsforhealth.org.uk/info-hub/dementia-2015-updated-2018/There are a variety of resources available on the NHS England E-learning for Health platform, including a programme on dementia care, designed to enhance the training and education of the health and social care workforceOur health system has struggled to support those with complex needs, including those with dementia. Under the 10-Year Health Plan, those living with dementia will benefit from improved care planning and better services.We will deliver the first ever Frailty and Dementia Modern Service Framework to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia and will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.